Liprolog Kwikpen (Insulin Lispro)

Liprolog Kwikpen contains insulin lispro, a rapid‑acting insulin analog that provides prandial glucose control for diabetes mellitus.

• Type 1 diabetes mellitus: improves post‑prandial glucose control and reduces hyperglycaemic excursions.
• Type 2 diabetes mellitus: offers rapid insulin coverage for meals, supporting overall glycaemic management.
• Insulin pump therapy (as a rapid‑acting bolus insulin): can be used for pump filling to deliver precise mealtime insulin doses.

• Insulin lispro binds to the insulin receptor on muscle and adipose cells, activating the receptor’s intrinsic tyrosine kinase activity. This triggers intracellular signaling cascades that promote translocation of GLUT‑4 transporters to the cell surface, enhancing glucose uptake. It also suppresses hepatic glucose production, leading to a rapid reduction in circulating blood glucose levels after injection.

Adverse reactions may occur with any insulin therapy.

Common Side Effects

• Hypoglycaemia: symptoms of low blood sugar such as shakiness, sweating, or confusion.
• Injection site reactions: redness, swelling, or itching at the injection site.
• Weight gain: modest increase in body weight with chronic use.

Serious or Rare Side Effects

• Severe hypoglycaemia: loss of consciousness or seizures requiring immediate medical attention.
• Anaphylactic reaction: hives, difficulty breathing, or throat swelling.
• Lipodystrophy: abnormal fat accumulation or loss at injection sites with repeated use.

Careful monitoring and patient education are essential when using rapid‑acting insulin analogs.

• Dose adjustment: regularly monitor blood glucose and adjust insulin dose as needed.
• Hypoglycaemia risk: educate patients on recognising and treating low blood sugar promptly.
• Renal impairment: consider dose reduction in patients with reduced kidney function.
• Pregnancy: use only if the expected benefit justifies the potential risk to the fetus.
• Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Insulin lispro may interact with several medications that affect glucose metabolism.

Major Interactions (Avoid)

• Beta‑blockers: can mask hypoglycaemia symptoms.
• Monoamine oxidase inhibitors (MAOIs): may potentiate insulin’s glucose‑lowering effect.
• Alcohol: enhances risk of hypoglycaemia, especially with fasting.

Moderate Interactions (Monitor Closely)

• Thiazide diuretics: may increase blood glucose levels.
• Corticosteroids: can raise glucose, requiring higher insulin doses.
• ACE inhibitors: may affect potassium balance, influencing insulin action.
• Oral contraceptives: may alter insulin sensitivity and glucose control.